Marseille, France

Noudjoud Attaf

This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique-Cnrs, Inserm (Institut National De La Santé Et De La Recherche Médicale), Université´ D'aix-Marseille. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Noudjoud Attaf. Retrieved from https://idiyas.com/inventor/noudjoud-attaf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Noudjoud Attaf: Inventor in RNA Sequencing

Introduction

Noudjoud Attaf is an inventor associated with Marseille, France. His work includes a patent focused on RNA sequencing and the analysis of immune-cell transcriptomes.

Latest Patents

Attaf is listed as an inventor on 1 patent: “RNA Sequencing Method for the Analysis of B and T Cell Transcriptome in Phenotypically Defined B and T Cell Subsets.” The invention concerns methods for examining gene-expression profiles in defined B- and T-cell populations.

Career Highlights

Attaf is associated with Inserm (French National Institute of Health and Medical Research) and the French National Centre for Scientific Research (CNRS). His patent reflects research at the intersection of sequencing methods and immune-cell analysis.

Collaborations

His listed collaborators include Pierre Milpied and Inaki Cervera-Marzal. Their shared work is represented by the patent on RNA sequencing in phenotypically defined B- and T-cell subsets.

Conclusion

Noudjoud Attaf’s patent highlights his contribution to methods for studying immune-cell transcriptomes through RNA sequencing.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…